Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke (SAFE)

NCT07423975 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.

NCT NCT07423975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07423975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke (SAFE)
Lead sponsor
Beijing Tiantan Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 1, 2026
Completion date
December 31, 2026
Enrollment
159 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endovascular treatment, stroke acute